Key result
Co-administration of RNAx with a saRNA-LNP vaccine decreased serum biomarkers of reactogenicity while maintaining or enhancing antibody and cellular responses in preclinical models.
Why the study?
RNA vaccine platforms trigger undesirable side effects at protective doses, underscoring the need for improved tolerability.
Population
Human primary cells and murine models
Comparison
Co-administration of leader-protein-encoding mRNA (RNAx) alongside vaccine cargo saRNA vs saRNA alone
Design
Preclinical laboratory and animal study
Authors
Loading...
RNAx co-administration may improve saRNA tolerability; leaves open clinical translation and efficacy trials.
Co-administration of a leader-protein-encoding mRNA (RNAx) with saRNA vaccines reduces reactogenicity while preserving or enhancing immunogenicity in preclinical models.
Wojcechowskyj et al. (2024) studied Vaccine reactogenicity. RNAx (leader-protein-encoding mRNA) was evaluated on Reactogenicity biomarkers and immunogenicity. Co-administration of RNAx with a saRNA-LNP vaccine decreased serum biomarkers of reactogenicity while maintaining or enhancing antibody and cellular responses in preclinical models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: